Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Clostridium Novyi-NT in Advanced Solid Tumors
NCT03435952Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2018
- Primary completion
- Oct 2026
- Modality
- Oncolytic Viruses, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Clostridium novyi-NT in solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 6 weeks. Started Jul 2018; status: completed.
02
Drugs
Clostridium novyi-NT
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03435952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03435952.